1. Biotech VC's 'Winning Formula' Faces Disruption as Chinese Science and AI Shift Investment Currents
The long-standing venture capital playbook for biotech—a formula of U.S. academic science, Big Pharma veterans, and massive capital—is now under direct pressure. The industry is confronting a dual disruption: the rapid, cost-effective rise of innovative research from Chinese scientists and the gravitational pull of art...